Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Molecular Pathway Deregulation”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Large-scale testing (Phase 3)Looking for participantsNCT03458221
What this trial is testing

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

Who this might be right for
Recurrent Ovarian CancerSignal Transduction Pathway DeregulationTherapy-Associated Cancer
Gynaecologisch Oncologisch Centrum Zuid 148
Not applicableUnknownNCT02863900
What this trial is testing

From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers

Who this might be right for
Breast Cancer
Institut Claudius Regaud 350
Not applicableStudy completedNCT04973033
What this trial is testing

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Who this might be right for
ANCA Associated VasculitisDrug UseJAK-STAT Pathway Deregulation
Shanghai Zhongshan Hospital 10
Not applicableLooking for participantsNCT05364294
What this trial is testing

Molecular Diagnosis of Systemic Autoinflammatory Diseases

Who this might be right for
Inflammatory DiseaseGenetic DiseaseSomatic Mutation+2 more
Institut National de la Santé Et de la Recherche Médicale, France 300
Not applicableLooking for participantsNCT05365412
What this trial is testing

Clinicopathological Characteristics of Colon Cancer in Young Age

Who this might be right for
Colo-rectal CancerMolecular Pathway Deregulation
Seoul National University Bundang Hospital 1,400
Not applicableStudy completedNCT03488641
What this trial is testing

Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer

Who this might be right for
Hematologic DiseasesTreatment
German Cancer Research Center 80
Testing effectiveness (Phase 2)Study completedNCT02372006
What this trial is testing

Trial of Afatinib in Pediatric Tumours

Who this might be right for
Neuroectodermal TumorsRhabdomyosarcoma
Boehringer Ingelheim 56
Not applicableStudy completedNCT03020108
What this trial is testing

Serum Caspase 3, Annexin a2 and Soluble Fas Levels and Endometriosis

Who this might be right for
EndometriosisApoptotic Pathway Deregulation
Bakirkoy Dr. Sadi Konuk Research and Training Hospital 90
Not applicableUnknownNCT03401957
What this trial is testing

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Who this might be right for
Colorectal CancerDrug ResistanceMass Spectrometry+1 more
National Health Research Institutes, Taiwan 120
Not applicableUnknownNCT04751279
What this trial is testing

Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells

Who this might be right for
SarcoidosisJAK-STAT Pathway Deregulation
Assistance Publique - Hôpitaux de Paris 80
Early research (Phase 1)Study completedNCT01868022
What this trial is testing

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Who this might be right for
Neoplasms
GlaxoSmithKline 65
Not applicableLooking for participantsNCT06830590
What this trial is testing

Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population

Who this might be right for
Breast CancerMolecular Pathway DeregulationTreatment
Liaquat University of Medical & Health Sciences 300
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableStudy completedNCT01789060
What this trial is testing

P-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Who this might be right for
Malignant LymphomaP13K-AKT Pathway Deregulation
Samsung Medical Center 262